MediWound Ltd. (MDWD)

NASDAQ: MDWD · Real-Time Price · USD
17.57
-0.96 (-5.18%)
Sep 18, 2024, 4:00 PM EDT - Market closed
-5.18%
Market Cap 189.52M
Revenue (ttm) 20.14M
Net Income (ttm) -19.97M
Shares Out 10.79M
EPS (ttm) -2.16
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 46,462
Open 18.69
Previous Close 18.53
Day's Range 17.53 - 18.77
52-Week Range 7.45 - 24.00
Beta 0.83
Analysts Strong Buy
Price Target 28.00 (+59.36%)
Earnings Date Aug 14, 2024

About MDWD

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other ha... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Mar 20, 2014
Employees 100
Stock Exchange NASDAQ
Ticker Symbol MDWD
Full Company Profile

Financial Performance

In 2023, MediWound's revenue was $18.69 million, a decrease of -29.48% compared to the previous year's $26.50 million. Losses were -$6.72 million, -65.73% less than in 2022.

Financial Statements

Analyst Forecast

According to one analyst, the rating for MDWD stock is "Strong Buy" and the 12-month stock price forecast is $28.0.

Price Target
$28.0
(59.36% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

MediWound Announces U.S. Food and Drug Administration Approval of NexoBrid® for the Treatment of Pediatric Patients with Severe Thermal Burns

Approval Helps Solidify NexoBrid's Position in the U.S. as a Safe and Effective Non-Surgical Burn Treatment for All Ages Approval Helps Solidify NexoBrid's Position in the U.S. as a Safe and Effective...

4 weeks ago - GlobeNewsWire

MediWound Ltd. (MDWD) Q2 2024 Earnings Call Transcript

MediWound Ltd. (NASDAQ:MDWD) Q2 2024 Earnings Conference Call August 14, 2024 8:30 AM ET Company Participants Gaia Shamis - IR, LifeSci Advisors Ofer Gonen - Chief Executive Officer Hani Luxenburg - ...

5 weeks ago - Seeking Alpha

MediWound Reports Second Quarter 2024 Financial Results and Provides Company Update

Completed Construction of New NexoBrid ® Manufacturing Facility €16.25 Million EIC Funding Expedites EscharEx ® Development for Diabetic Foot Ulcer s , Significantly Expanding the Addressable Market ;...

5 weeks ago - GlobeNewsWire

MediWound Announces Positive Results from the U.S. NexoBrid® Expanded Access Protocol (NEXT)

NEXT Confirms NexoBrid's Proven Safety and Efficacy in Eschar Removal, Significantly Reducing Surgical Procedures for Burn Patients NEXT Confirms NexoBrid's Proven Safety and Efficacy in Eschar Remova...

6 weeks ago - GlobeNewsWire

MediWound to Report Second Quarter 2024 Financial Results

Conference Call and Webcast Scheduled for Wednesday, August 14th at 8:30 am Eastern Time Conference Call and Webcast Scheduled for Wednesday, August 14th at 8:30 am Eastern Time

6 weeks ago - GlobeNewsWire

MediWound Announces Publication of the EscharEx® Phase II ChronEx Study Results for Venous Leg Ulcers

Research Published in THE LANCET's eClinicalMedicine EscharEx ® Outperforms Non-Surgical Standard of Care in Debridement and Promotion of Healthy Granulation Tissue

7 weeks ago - GlobeNewsWire

MediWound Announces €16.25 Million Funding from the European Innovation Council Accelerator Program

Funds to be used for clinical development of EscharEx ® to treat diabetic foot ulcers (DFUs)

2 months ago - GlobeNewsWire

Mölnlycke® Health Care announces US $15m investment in next-generation enzymatic therapeutics company MediWound Ltd

GOTHENBURG, Sweden , July 15, 2024 /PRNewswire/ -- Mölnlycke Health Care, a world-leading MedTech company specialising in solutions for wound care and surgical procedures, announced today an investmen...

2 months ago - PRNewsWire

MediWound Announces $25 Million Strategic Private Placement Financing

Mölnlycke Health Care, a global leader in innovative wound care solutions, leads the PIPE with a $15 million investment Mölnlycke Health Care, a global leader in innovative wound care solutions, leads...

2 months ago - GlobeNewsWire

MediWound Ltd. (MDWD) Q1 2024 Earnings Call Transcript

MediWound Ltd. (NASDAQ:MDWD) Q1 2024 Earnings Conference Call May 29, 2024 8:30 AM ET Company Participants Ofer Gonen - Chief Executive Officer Hani Luxenburg - Chief Financial Officer Barry Wolfenso...

4 months ago - Seeking Alpha

MediWound Reports First Quarter 2024 Financial Results and Provides Company Update

NexoBrid® interest surges; $5 million in Q1 2024 revenue, with $24 million forecast for the year Manufacturing facility on target for completion by mid-2024 EscharEx® Phase III study to launch 2H 2024...

4 months ago - GlobeNewsWire

MediWound to Report First Quarter 2024 Financial Results

Conference Call and Webcast Scheduled for Wednesday, May 29th at 8:30 am Eastern Time Conference Call and Webcast Scheduled for Wednesday, May 29th at 8:30 am Eastern Time

4 months ago - GlobeNewsWire

MediWound to Present New Data from EscharEx® Phase II Studies at Three Leading Wound Care Conferences

Oral presentations include additional comparative data between EscharEx ® and SANTYL ® , and new analyses show strong correlation between wound bed preparation and wound healing

5 months ago - GlobeNewsWire

MediWound Ltd. (MDWD) Q4 2023 Earnings Call Transcript

MediWound Ltd. (MDWD) Q4 2023 Earnings Call Transcript

6 months ago - Seeking Alpha

MediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update

$19 million revenue in 2023; $24 million projected revenue in 2024 NexoBrid ® commercially launched in U.S., Japan, India Potential blockbuster EscharEx ® to begin Phase III in the second half of 2024...

6 months ago - GlobeNewsWire

MediWound to Report Fourth Quarter and Full Year 2023 Financial Results

Conference Call and Webcast Scheduled for Thursday, March 21st at 8:30 am Eastern Time Conference Call and Webcast Scheduled for Thursday, March 21st at 8:30 am Eastern Time

6 months ago - GlobeNewsWire

MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled Study

Results demonstrate superiority of EscharEx®, a bromelain-based gel vs. SANTYL®, a collagenase ointment, in wound debridement, promotion of granulation tissue, and time to wound closure in patients wi...

7 months ago - GlobeNewsWire

MediWound to Participate in Two Upcoming Investor Conferences

YAVNE, Israel, Feb. 05, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today ...

8 months ago - GlobeNewsWire

MediWound Announces that FDA has Accepted for Review the Supplement to the NexoBrid BLA to Include Pediatric Patients with Severe Thermal Burns

If approved, NexoBrid will serve as an effective non-surgical treatment for both pediatric and adult burn patients in the U.S.

9 months ago - GlobeNewsWire

MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid® Development for the U.S. Army

Awarded additional $6.7 million to advance NexoBrid as a non-surgical field care solution; R&D project budget increased to $14.4 million Awarded additional $6.7 million to advance NexoBrid as a non-su...

9 months ago - GlobeNewsWire

MediWound Announces Peer-Reviewed Publication of EscharEx® Mechanism of Action Study Assessing Its Effects on Biofilm and Microbial Loads

Results show EscharEx to be safe and effective, and suggest it can go beyond traditional expectations for enzymatic debridement Results show EscharEx to be safe and effective, and suggest it can go be...

9 months ago - GlobeNewsWire

MediWound Ltd. (MDWD) Q3 2023 Earnings Call Transcript

MediWound Ltd. (NASDAQ:MDWD) Q3 2023 Earnings Call Transcript November 21, 2023 8:30 AM ET Company Participants Daniel Ferry - LifeSci Advisors Ofer Gonen - Chief Executive Officer Barry Wolfenson - ...

10 months ago - Seeking Alpha

MediWound Reports Third Quarter 2023 Financial Results and Provides Company Update

NexoBrid® commercially launched in U.S. and Japan; Company prioritizes operational resources to meet increased global demand

10 months ago - GlobeNewsWire

MediWound Announces Appointment of Shmulik Hess, Ph.D. as Chief Operating Officer and Chief Commercial Officer

YAVNE, Israel, Nov. 21, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today ...

10 months ago - GlobeNewsWire

MediWound to Report Third Quarter 2023 Financial Results

Conference Call and Webcast Scheduled for Tuesday, November 21st at 8:30 am Eastern Time Conference Call and Webcast Scheduled for Tuesday, November 21st at 8:30 am Eastern Time

11 months ago - GlobeNewsWire